By Dr Bianca Crook, South African general
practitioner
Medically reviewed: 1 September 2026
When GLP-1 treatment stops, its appetite and metabolic effects diminish over time. Hunger or food-related thoughts may increase, and weight regain is common, although the amount and timing vary. Stopping is not a moral failure. It is a point at which the treatment team should reassess health goals, nutrition, activity, other medicines and the maintenance plan.
Key points
- Do not assume that all benefits will remain unchanged after the medicine is withdrawn.
- Trials show substantial average regain after stopping semaglutide or switching from tirzepatide to placebo.
- Individual experiences vary; trial averages do not predict one person exactly.
- Plan for affordability, supply, pregnancy, surgery and adverse effects before a crisis.
- Do not restart at an old high dose after a gap without clinical advice.
What withdrawal trials tell us
In the STEP 1 trial extension, participants who stopped semaglutide 2.4 mg after 68 weeks regained about two-thirds of their prior weight loss over the following year on average. Cardiometabolic improvements also moved back toward baseline. In SURMOUNT-4, people who continued tirzepatide maintained and extended weight loss, while those switched to placebo regained substantial weight.
These findings support a chronic-disease model: the biology that contributed to weight gain does not necessarily disappear because weight has been lost. They do not mean that every patient must remain on one medicine forever, nor do they mean that everyone regains the same amount.
Why appetite may feel different
GLP-1 and GIP/GLP-1 medicines can reduce hunger, increase fullness and change food cravings. As the medicine leaves the body, those effects may fade. Weight loss itself can also increase biological pressure to eat and reduce energy expenditure.
Some patients describe the return as “food noise.” Others notice larger portions, earlier hunger or less satisfaction after meals. Read What Is Food Noise - and Why Can It Return? for a non-judgemental way to track the experience.
Reasons treatment may stop
Stopping may be planned or unplanned. Common reasons include adverse effects, cost, shortages, pregnancy planning, a procedure, insufficient benefit, a change in health, or a personal decision after discussion with the clinician.
Each reason creates a different plan. Pregnancy advice is medicine-specific. Perioperative decisions depend on the procedure, symptoms, aspiration risk and current anaesthesia guidance. A temporary supply interruption is not the same as a permanent stop.
Do not use a generic internet schedule for tapering or restarting. Some medicines do not require a pharmacological taper, but appetite and glucose effects still change, and a long interruption may affect the safe restart dose. People with diabetes may need closer glucose monitoring and an alternative treatment plan.
Build a maintenance plan
A maintenance plan can include:
- the health outcomes being monitored, not only weight;
- a realistic eating pattern with adequate protein and fibre;
- strength and aerobic activity appropriate to the person;
- sleep, mental-health and social support;
- a schedule for follow-up and laboratory monitoring where indicated;
- a threshold for contacting the clinician if appetite, glucose or weight changes;
- discussion of continued treatment, another medicine or non-drug options where appropriate.
Maintenance is not a single number or a promise never to regain. It is an organised response to a chronic condition.
If weight begins to return
First, look at the trend rather than one measurement. Review changes in appetite, eating pattern, activity, sleep, stress, medicines and health. Avoid crash dieting, which can worsen food preoccupation and threaten lean tissue.
Arrange follow-up if the change is persistent or clinically important. The clinician can review whether treatment should be resumed, changed or supported in another way. Do not borrow another person’s pen or restart at the previous dose without advice.
If you are considering the medicine for the first time, What Should a Patient Know Before Starting a GLP-1 Medicine? explains why the stopping plan belongs in the first consultation.
Recurrence is not failure
Weight recurrence after withdrawal reflects the interaction of biology, environment, behaviour and treatment duration. Shame does not improve the plan. A clinician should address recurrence in the same practical way as the return of blood pressure or glucose problems after a treatment change: reassess, identify risk and decide what support is appropriate.
For a detailed guide to GLP-1 maintenance, plateaus and weight recurrence, see Before Your Next Injection.
Medical disclaimer: This article is general education. Stopping or restarting treatment can affect appetite, weight and glucose. Do not stop, restart or change a prescription medicine without a clinician-led plan, especially if you have diabetes or are pregnant or planning pregnancy.
Sources: STEP 1 trial extension; SURMOUNT-4 randomised clinical trial; WHO guidance on GLP-1 therapies for obesity; current approved product information.